Nadofaragene firadenovec clinical trials
Also written SCH 721015, INSTILADRIN and rAd-IFN.
How each study uses nadofaragene firadenovec is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the nadofaragene firadenovec studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 16 Dec 2022 · Adstiladrin · BLA 125700 (FDA, Purple Book)
- European Union
- 28 May 2026 · Adstiladrin · EMEA/H/C/005856 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2016 | 1 |
| 2019 | 1 |
| 2022 | 1 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 7
Ferring Pharmaceuticals (6) · Abramson Cancer Center at Penn Medicine (2) · Ferring Ventures Limited (1) · University of Pennsylvania (1) · FKD Therapies Oy (1) · M.D. Anderson Cancer Center (1) · University of Washington (1) · Memorial Sloan Kettering Cancer Center (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test nadofaragene firadenovec.
- Jun 2027Neoadjuvant Intravesical Nadofaragene Firadenovec With Enfortumab Vedotin and Pembrolizumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA TrialPhase 2 · University of Washington
Studies
Open first, then newest update. How each study uses nadofaragene firadenovec is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 15
- Neoadjuvant Intravesical Nadofaragene Firadenovec With Enfortumab Vedotin and Pembrolizumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA TrialNot yet recruitingPhase 2University of WashingtonNCT07332351Written as Nadofaragene FiradenovecHow we know
- Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder CancerRecruitingPhase 3Ferring PharmaceuticalsNCT06510374Written as Nadofaragene FiradenovecHow we know
- A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder CancerRecruitingPhase 3Ferring PharmaceuticalsNCT06545955Written as Nadofaragene FiradenovecHow we know
- Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal PelvisRecruitingPhase 1/2Ferring PharmaceuticalsNCT06668493Written as Nadofaragene FiradenovecHow we know
- A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)RecruitingPhase 3Memorial Sloan Kettering Cancer CenterNCT06929286Written as Nadofaragene FiradenovecHow we know
- TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic AdenocarcinomaRecruitingPhase 1University of California, DavisNCT07189195Written as TR-002How we know
- Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)Active, not recruitingPhase 3Ferring PharmaceuticalsNCT05704244Written as FE 999326How we know
- Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural MesotheliomaCompletedPhase 3Ferring Ventures LimitedNCT03710876Written as rAd-IFNHow we know
- A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.WithdrawnPhase 4Ferring PharmaceuticalsNCT06390111Written as nadofaragene firadenovecHow we know
- ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)CompletedPhase 3Ferring PharmaceuticalsNCT02773849Written as ADSTILADRINHow we know
- Gene Therapy for Pleural MalignanciesCompletedPhase 1University of PennsylvaniaNCT00299962Written as SCH 721015How we know
- Combination Gene Transfer and ChemotherapyCompletedPhase 1Abramson Cancer Center at Penn MedicineNCT01119664Written as SCH 721015How we know
- Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder CancerCompletedPhase 2FKD Therapies OyNCT01687244Written as INSTILADRINHow we know
- 1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder CancerCompletedPhase 1M.D. Anderson Cancer CenterNCT01162785Written as SCH 721015How we know
- Intrapleural Gene Transfer for Pleural MesotheliomaCompletedPhase 1Abramson Cancer Center at Penn MedicineNCT01212367Written as SCH 721015How we know
Codes
What other systems call nadofaragene firadenovec · ClinicalTrials.gg INT002127
- MeSH (NLM) C000731690nadofaragene firadenovecOne source NLM
- UNII (FDA) 0OOS09O1FHNADOFARAGENE FIRADENOVECConfirmed FDA, NLM
- NCI Thesaurus C71011Nadofaragene FiradenovecOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731690 | nadofaragene firadenovec | One source NLM |
| UNII (FDA) | 0OOS09O1FH | NADOFARAGENE FIRADENOVEC | Confirmed FDA, NLM |
| NCI Thesaurus | C71011 | Nadofaragene Firadenovec | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.